Year Founded
2008
Ownership
Public
Therapeutic Areas
Infectious DiseasesOncologyOphthalmology
Stage
Phase 3
Modalities
Small moleculeLiposome formulationSmall moleculeSmall molecule

SynCore Biotechnology General Information

Lead asset SB05PC (EndoTAG-1) is in Phase 3 for pancreatic cancer with interim analysis results received. Multiple other programs in development including SB03 (Veregen) for external genital warts and SB04 for age-related macular degeneration.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

SB01/02
Development
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to SynCore Biotechnology's pipeline data

Book a demo

Key Partnerships

National Health Research Institute Taiwan, Sinphar Group

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

SynCore Biotechnology Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view SynCore Biotechnology's complete valuation and funding history, request access »

SynCore Biotechnology Investors

Sinphar Group/Sinphar Pharmaceutical Co., Ltd.
Investor Type: Venture Capital
Holding: Minority
National Health Research Institute Taiwan
Investor Type: Venture Capital
Holding: Minority